Whatever you do, don’t call it a festival. There’s no set schedule or events during the two-day gathering, warns Dave Shenkman, owner of Kite Connection on the Huntington Beach Pier and ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all ...

Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are currently covering the stock, MarketBeat Ratings reports.

New Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today and set a price target of $37.00. The company’s shares closed ...

Shareholders of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) will be pleased this week, given that the stock price is up 13% to US$20.91 following its latest full-year results. Revenues came in ...

Shares of NAMS opened at $17.53 on Tuesday. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29. The stock’s 50-day moving average price is $23.03 and its two-hundred day ...

Revenue: US$45.6m (up 223% from FY 2023). Net loss: US$241.6m (loss widened by 37% from FY 2023). US$2.56 loss per share (further deteriorated from US$2.15 loss in FY 2023). Revenue exceeded ...

Lucas Hunter loves to kite surf, so along with his sister Sophie he planned a trip to Colombia to take advantage of the “good waves” in the north of the country in late December last year.

Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $41 from $35 and keeps a Buy rating on the shares. Compared to prior CETPi’s ...

Mankind Pharma, India’s fourth largest drugmaker by domestic sales, is setting its sights on anti-obesity drugs like Semaglutide, better known by brand names Ozempic and Wegovy, which goes off ...